Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages

Journal of Controlled Release

Volumn 150, Issue 2, 2011, Pages 204-211

  Nowacek, Ari S ^a   Balkundi, Shantanu ^a   McMillan, Joellyn ^a   Roy, Upal ^a   Martinez Skinner, Andrea ^a   Mosley, R Lee ^a,b   Kanmogne, Georgette ^a   Kabanov, Alexander V ^a,b   Bronich, Tatiana ^a,b   Gendelman, Howard E ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Antiretroviral; Crystalline; HIV; Macrophage; Monocyte; Nanomedicine; Nanoparticles

Indexed keywords

ANTIRETROVIRALS; CRYSTALLINE; HIV; MONOCYTE; NANOMEDICINES;

BODY FLUIDS; CRYSTALLINE MATERIALS; CURRICULA; DRUG INTERACTIONS; DRUG PRODUCTS; MACROPHAGES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; SURFACE ACTIVE AGENTS; VIRUSES;

DISEASES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DODECYL SULFATE SODIUM; EFAVIRENZ; INDINAVIR; MACROGOL 2000; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; POLYVINYL ALCOHOL; RITONAVIR; SURFACTANT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG COATING; DRUG EFFICACY; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MOLECULAR INTERACTION; MONOCYTE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCORING SYSTEM; SURFACE CHARGE; VIRUS REPLICATION; ZETA POTENTIAL;

ANTI-RETROVIRAL AGENTS; BENZOXAZINES; HIV-1; HUMANS; INDINAVIR; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; PYRIDINES; RITONAVIR; STATIC ELECTRICITY; SURFACE-ACTIVE AGENTS; VIRUS REPLICATION;

EID: 79952985878     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.11.019     Document Type: Article

References (53)

1. S. Broder The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Antivir. Res. 85 2010 1 18
2. J.A. Este, and T. Cihlar Current status and challenges of antiretroviral research and therapy Antivir. Res. 85 2010 25 33
3. S. Moreno, J. Lopez Aldeguer, J.R. Arribas, P. Domingo, J.A. Iribarren, E. Ribera, A. Rivero, and F. Pulido The future of antiretroviral therapy: challenges and needs J. Antimicrob. Chemother. 65 2010 827 835
4. K.S. Rao, A. Ghorpade, and V. Labhasetwar Targeting anti-HIV drugs to the CNS Expert Opin. Drug Deliv. 6 2009 771 784
5. L. Varatharajan, and S.A. Thomas The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research Antivir. Res. 82 2009 A99 A109
6. R. Mallipeddi, and L.C. Rohan Progress in antiretroviral drug delivery using nanotechnology Int. J. Nanomedicine 5 2010 533 547
7. H.L. Wong, N. Chattopadhyay, X.Y. Wu, and R. Bendayan Nanotechnology applications for improved delivery of antiretroviral drugs to the brain Adv. Drug Deliv. Rev. 62 2010 503 517
8. A. Nowacek, and H.E. Gendelman NanoART, neuroAIDS and CNS drug delivery Nanomedicine 4 2009 557 574
9. J. das Neves, M.M. Amiji, M.F. Bahia, and B. Sarmento Nanotechnology-based systems for the treatment and prevention of HIV/AIDS Adv. Drug Deliv. Rev. 62 2010 458 477
10. Z.M. Chirenje, J. Marrazzo, and U.M. Parikh Antiretroviral-based HIV prevention strategies for women Expert Rev. Anti-Infect. Ther. 8 2010 1177 1186
11. C.J. Destache, T. Belgum, K. Christensen, A. Shibata, A. Sharma, and A. Dash Combination antiretroviral drugs in PLGA nanoparticle for HIV-1 BMC Infect. Dis. 9 2009 198
12. H. Dou, C.J. Destache, J.R. Morehead, R.L. Mosley, M.D. Boska, J. Kingsley, S. Gorantla, L. Poluektova, J.A. Nelson, M. Chaubal, J. Werling, J. Kipp, B.E. Rabinow, and H.E. Gendelman Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery Blood 108 2006 2827 2835
13. H. Dou, C.B. Grotepas, J.M. McMillan, C.J. Destache, M. Chaubal, J. Werling, J. Kipp, B. Rabinow, and H.E. Gendelman Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS J. Immunol. 183 2009 661 669
14. S.D. Mahajan, I. Roy, G. Xu, K.T. Yong, H. Ding, R. Aalinkeel, J. Reynolds, D. Sykes, B.B. Nair, E.Y. Lin, P.N. Prasad, and S.A. Schwartz Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles Curr. HIV Res. 8 2010 396 404
15. U.M. Parikh, C. Dobard, S. Sharma, M.E. Cong, H. Jia, A. Martin, C.P. Pau, D.L. Hanson, P. Guenthner, J. Smith, E. Kersh, J.G. Garcia-Lerma, F.J. Novembre, R. Otten, T. Folks, and W. Heneine Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine J. Virol. 83 2009 10358 10365
16. L. Yang, L. Chen, R. Zeng, C. Li, R. Qiao, L. Hu, and Z. Li Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5′-O-d4T monophosphate conjugate Bioorg. Med. Chem. 18 2010 117 123
17. P. Benaroch, E. Billard, R. Gaudin, M. Schindler, and M. Jouve HIV-1 assembly in macrophages Retrovirology 7 2010 29
18. M.J. Kuroda Macrophages: do they impact AIDS progression more than CD4 T cells? J. Leukoc. Biol. 87 2010 569 573
19. V. Le Douce, G. Herbein, O. Rohr, and C. Schwartz Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage Retrovirology 7 2010 32
20. Y. Persidsky, and H.E. Gendelman Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection J. Leukoc. Biol. 74 2003 691 701 (Pubitemid 38040345)
21. H. Dou, J. Morehead, C.J. Destache, J.D. Kingsley, L. Shlyakhtenko, Y. Zhou, M. Chaubal, J. Werling, J. Kipp, B.E. Rabinow, and H.E. Gendelman Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages Virology 358 2007 148 158 (Pubitemid 46048870)
22. A.S. Nowacek, J. McMillan, R. Miller, A. Anderson, B. Rabinow, and H.E. Gendelman Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics J. Neuroimmune Pharmacol. 5 2010 592 601
23. A.S. Nowacek, R.L. Miller, J. McMillan, G. Kanmogne, M. Kanmogne, R.L. Mosley, Z. Ma, S. Graham, M. Chaubal, J. Werling, B. Rabinow, H. Dou, and H.E. Gendelman NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery Nanomedicine 4 2009 903 917
24. M. Caldorera-Moore, N. Guimard, L. Shi, and K. Roy Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers Expert Opin. Drug Deliv. 7 2010 479 495
25. N. Doshi, and S. Mitragotri Needle-shaped polymeric particles induce transient disruption of cell membranes J. R. Soc. Interface 7 Suppl 4 2010 S403 S410
26. X. Huang, X. Teng, D. Chen, F. Tang, and J. He The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function Biomaterials 31 2010 438 448
27. B.S. Zolnik, A. Gonzalez-Fernandez, N. Sadrieh, and M.A. Dobrovolskaia Nanoparticles and the immune system Endocrinology 151 2010 458 465
28. Y. Tanaka, M. Inkyo, R. Yumoto, J. Nagai, M. Takano, and S. Nagata Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders Chem. Pharm. Bull. (Tokyo) 57 2009 1050 1057
29. J. Hu, K.P. Johnston, and R.O. Williams III Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs Drug Dev. Ind. Pharm. 30 2004 233 245 (Pubitemid 38451748)
30. H.E. Gendelman, J.M. Orenstein, M.A. Martin, C. Ferrua, R. Mitra, T. Phipps, L.A. Wahl, H.C. Lane, A.S. Fauci, and D.S. Burke Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes J. Exp. Med. 167 1988 1428 1441
31. D.C. Kalter, M. Nakamura, J.A. Turpin, L.M. Baca, D.L. Hoover, C. Dieffenbach, P. Ralph, H.E. Gendelman, and M.S. Meltzer Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes J. Immunol. 146 1991 298 306
32. T. Takatsuka, T. Endo, Y. Jianguo, K. Yuminoki, and N. Hashimoto Nanosizing of poorly water soluble compounds using rotation/revolution mixer Chem. Pharm. Bull. (Tokyo) 57 2009 1061 1067
33. B. Van Eerdenbrugh, L. Froyen, J.A. Martens, N. Blaton, P. Augustijns, M. Brewster, and G. Van den Mooter Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling Int. J. Pharm. 338 2007 198 206 (Pubitemid 46779149)
34. B.D. Chithrani, A.A. Ghazani, and W.C. Chan Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells Nano Lett. 6 2006 662 668
35. S.E. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, and J.M. DeSimone The effect of particle design on cellular internalization pathways Proc. Natl Acad. Sci. USA 105 2008 11613 11618
36. D.S. Wishart, C. Knox, A.C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and M. Hassanali DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 36 2008 D901 D906
37. D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey DrugBank: a comprehensive resource for in silico drug discovery and exploration Nucleic Acids Res. 34 2006 D668 D672
38. B.S. Robinson, K.A. Riccardi, Y.F. Gong, Q. Guo, D.A. Stock, W.S. Blair, B.J. Terry, C.A. Deminie, F. Djang, R.J. Colonno, and P.F. Lin BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents Antimicrob. Agents Chemother. 44 2000 2093 2099 (Pubitemid 30484432)
39. M. Shannon, S. Borron, and M. Burns Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose 4th ed. 2007 Saunders Elsevier Philadelphia, PA
40. N. von Hentig, E. Babacan, T. Lennemann, G. Knecht, A. Carlebach, S. Harder, S. Staszewski, and A. Haberl The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors J. Antimicrob. Chemother. 62 2008 579 582
41. W. Jiang, B.Y. Kim, J.T. Rutka, and W.C. Chan Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 3 2008 145 150 (Pubitemid 351355131)
42. H. Vallhov, S. Gabrielsson, M. Stromme, A. Scheynius, and A.E. Garcia-Bennett Mesoporous silica particles induce size dependent effects on human dendritic cells Nano Lett. 7 2007 3576 3582
43. I. Slowing, B.G. Trewyn, and V.S. Lin Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells J. Am. Chem. Soc. 128 2006 14792 14793 (Pubitemid 44851603)
44. M. Ferrari Nanogeometry: beyond drug delivery Nat. Nanotechnol. 3 2008 131 132 (Pubitemid 351355138)
45. M. Roser, D. Fischer, and T. Kissel Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats Eur. J. Pharm. Biopharm. 46 1998 255 263 (Pubitemid 29057671)
46. P.A. Garvie, J. Lawford, P.M. Flynn, A.H. Gaur, M. Belzer, G.D. McSherry, and C. Hu Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability J. Adolesc. Health 44 2009 124 132
47. T. Hawkins Appearance-related side effects of HIV-1 treatment AIDS Patient Care STDs 20 2006 6 18 (Pubitemid 43172777)
48. S.W. Royal, D.P. Kidder, S. Patrabansh, R.J. Wolitski, D.R. Holtgrave, A. Aidala, S. Pals, and R. Stall Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV AIDS Care 21 2009 448 455
49. C. Danel, R. Moh, M.L. Chaix, D. Gabillard, J. Gnokoro, C.J. Diby, T. Toni, L. Dohoun, C. Rouzioux, E. Bissagnene, R. Salamon, and X. Anglaret Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults J. Infect. Dis. 199 2009 66 76
50. C.S. Meade, N.B. Hansen, A. Kochman, and K.J. Sikkema Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse AIDS Patient Care STDs 23 2009 259 266
51. M.K. Baum, C. Rafie, S. Lai, S. Sales, B. Page, and A. Campa Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users J. Acquir. Immune Defic. Syndr. 50 2009 93 99
52. L. Baert, G. van 't Klooster, W. Dries, M. Francois, A. Wouters, E. Basstanie, K. Iterbeke, F. Stappers, P. Stevens, L. Schueller, P. Van Remoortere, G. Kraus, P. Wigerinck, and J. Rosier Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment Eur. J. Pharm. Biopharm. 72 2009 502 508
53. G. van 't Klooster, E. Hoeben, H. Borghys, A. Looszova, M.P. Bouche, F. van Velsen, and L. Baert Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation Antimicrob. Agents Chemother. 54 2010 2042 2050